Chison E4-13 Ultrasound Probe Transvaginal Transducer for Sonomax

Name: Chison E4-13 Ultrasound Probe Transvaginal Transducer for Sonomax
Brand: Shenzhen Reyardmed Technology Limited.
SKU: 2091875312

Guangdong, ChinaShenzhen Reyardmed Technology Limited.

US$1,000.00-5,000.00

1 Piece

Product profile

Customization

Available

Customized

Certification

CE, FDA, ISO13485

Model NO.

E4-13

Scale

Medium

Brand

Chison

Model

E4-13

Type

Transvaginal

Frequency

6.5MHz

Compatible Systems

Sonomax

Applications

Ob/Gyn, Msk, Gi

Materials

Metal, Pastics

Warranty

Six Months

Transport Package

Common Box

Origin

China

HS Code

9018129190

Production Capacity

50000PCS/Year

Key features

CE, FDA, ISO13485 Certified: Meets international quality and safety standards for medical devices.

Customized Brand and Model: Brand and model can be customized according to specific requirements.

Multi-Application Support: Suitable for OB/GYN, Abdomen, MSK, and GI applications.

Durable Material Construction: Manufactured with high-standard metal and plastics for longevity.

Global Market Reach: Serves healthcare providers across six continents with local support.

Comprehensive Repair Services: Offers rapid, cost-effective servicing with a 100% quality guarantee.

Competitive Pricing Strategy: Delivers high-performance tools at competitive market prices.

Company profile

Shenzhen Reyardmed Technology Limited.

Guangdong, China

Business Type: Trading CompanyAverage Response Time: ≤1.01h

AI-Powered supplier vetting

SummaryThe supplier is a limited trading company offering ultrasound probes and related medical-device, technology, rental, consulting, and trading services. It reports ISO 13485 certification, 11–20 years of combined R&D-engineer experience, 6–10 quality-control staff, broad export coverage, and order fulfillment within 15 working days in both peak and off-peak periods. However, it does not provide OEM services for popular brands or an SDK, and the available quality-control evidence identifies zero quality-control test equipment, no written corrective/preventive-action or complaint-handling procedures, and unknown quality-assurance and traceability status. Financial records are referenced for 2022–2024, but no usable financial performance figures are provided. Customer relationships across multiple regions are described, but no specific customer cases are named.

CertificationsThe supplier reports holding ISO 13485 certification, a medical-device quality-management certification. The slices do not provide the certificate number, validity period, certification scope, or product coverage, so the certification is evidenced but its applicability cannot be fully assessed.

After-Sales capabilityThe supplier describes support from pre-sales consultation through after-sales technical assistance and states that it serves hospitals, clinics, and distributors internationally. However, it also reports no written procedures or records for corrective and preventive actions or customer-complaint handling, which shows a documented service-process deficiency despite the stated support commitment.

Production capacityThe supplier offers ultrasound probes, reports an annual production-output range, exports to multiple regions, and states order fulfillment within 15 working days in both peak and off-peak seasons. Against these positive operational indicators, the quality-control slice reports zero quality-control test equipment and unknown quality-assurance and traceability status, creating a clear documented weakness in production-quality infrastructure.

Customization capabilityThe supplier lists technology development, consultation, exchange, transfer, and technical services, and has reported R&D-engineer experience. However, it explicitly does not provide OEM services for popular brands and has no available SDK; no other product-customization process or capabilities are documented.